Drug Trial Radar · NCT05715840
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
Last checked: Nov 19, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
368
Planned (sponsor's estimate)
Start
Jan 31, 2023
Primary completion
Jul 31, 2024
Study completion May 31, 2026
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomised, double-blind, placebo-controlled, multicentre phase 3 clinical study to evaluate the efficacy and safety of SG001 plus chemotherapy±bevacizumab versus placebo plus chemotherapy±bevacizumab, as first-line treatment, in patients with PD-L1 positive (CPS≥1), Recurrent or Metastatic Cervical Cancer. The study contains a Safety Lead-in Phase in which the safety and tolerability of SG001+Chemotherapy±Bevacizumab will be assessed prior to the Phase 3 portion of the study.
Conditions
- Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
Interventions
SG001 injectionDrug
360 mg,Q3W,IV infusion
PaclitaxelDrug
175 mg/m\^2,Q3W,IV infusion
CisplatinDrug
50 mg/m\^2,Q3W,IV infusion
CarboplatinDrug
AUC=5,Q3W,IV infusion
Bevacizumab injectionDrug
15 mg/kg,Q3W,IV infusion
SG001 placeboDrug
Q3W,IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Lead-inTime frame: Up to 42 days after the last patient of the lead-in phase
- PFS per RECIST 1.1Time frame: Up to approximately 3 years
- Overall survival (OS)Time frame: Up to approximately 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.